Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 9/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | GHSR | Q92847 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4105637 | 1.00 | REN (0.42) | RENDRD2SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4105634 | 1.00 | REN (0.42) | RENDRD2SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4534526 | 0.92 | REN (0.43) | RENDRD2SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4534521 | 0.92 | REN (0.43) | RENDRD2SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4534519 | 0.92 | REN (0.43) | RENDRD2SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4106497 | 0.90 | REN (0.44) | RENDRD2SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4106499 | 0.90 | REN (0.44) | RENDRD2SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3911207 | 0.90 | REN (0.44) | RENDRD2SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4527408 | 0.89 | REN (0.45) | RENCYP3A4 | |
| SCHEMBL4527413 | 0.89 | REN (0.45) | RENCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | REN, ACE, AGTR1 | REN 1/4885DRD2 308/4885SLC6A4 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.